FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4292308669> ?p ?o ?g. }

• W4292308669 abstract "The clinical efficacy of current therapies for Hepatocellular carcinoma (HCC) are unsatisfactory. In recent years, chimeric antigen receptor (CAR) T-cell therapies have been developed for solid tumors including advanced HCC (aHCC), but limited progress has been made. Glypican-3 is a promising immunotherapeutic target for HCC since it is specifically highly expressed in HCC. A previous study indicated that GPC3-targeted CAR T-(CAR-GPC3) cells were well-tolerated and had prolonged survival for HCC patients and that Sorafenib could increase the antitumor activities of CAR-GPC3 T-cells against HCC in mouse models. Here, we report a patient with aHCC who achieved a complete response (CR) and a long survival period after the combination therapy of CAR-GPC3 T-cell plus sorafenib. A 60-year-old Asian male diagnosed with hepatitis B virus (HBV) related HCC developed liver recurrence and lung metastasis after liver tumor resection and trans-arterial chemoembolization therapy. The patient also previously received microwave ablation therapy for lung metastasis. After the enrollment, the patient underwent leukapheresis for CAR-GPC3 T-cells manufacturing. Seven days after leukapheresis, the patient started to receive 400 mg of Sorafenib twice daily. The patient received 4 cycles of CAR-GPC3 T cells (CT011) treatment and each cycle was divided into two infusions. Prior to each cycle of CT011 treatment, lymphodepletion was performed. The lymphodepletion regimen was cyclophosphamide 500 mg/m2/day for 2 to 3 days, and fludarabine 20-25 mg/m2/day for 3 to 4 days. A total of 4×109 CAR-GPC3 T cells were infused. The CT011 plus Sorafenib combination therapy was well tolerated. All the ≥ grade 3 AEs were hematological toxicities which were deemed an expected event caused by the preconditioning regimen. This patient obtained partial responses from the 3rd month and achieved CR in the 12th month after the first cycle of CT011 infusion according to the RECIST1.1 assessment. The tumor had no progression for more than 36 months and maintained the CR status for more than 24 months after the first infusion." @default.
• W4292308669 created "2022-08-19" @default.
• W4292308669 creator A5012143979 @default.
• W4292308669 creator A5012541451 @default.
• W4292308669 creator A5014345054 @default.
• W4292308669 creator A5020392344 @default.
• W4292308669 creator A5036977660 @default.
• W4292308669 creator A5046001715 @default.
• W4292308669 creator A5046597133 @default.
• W4292308669 creator A5048449740 @default.
• W4292308669 creator A5052390898 @default.
• W4292308669 creator A5060427946 @default.
• W4292308669 creator A5061599798 @default.
• W4292308669 creator A5065058975 @default.
• W4292308669 creator A5079375772 @default.
• W4292308669 creator A5081242848 @default.
• W4292308669 creator A5091365015 @default.
• W4292308669 date "2022-08-17" @default.
• W4292308669 modified "2023-10-18" @default.
• W4292308669 title "Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report" @default.
• W4292308669 cites W1487455823 @default.
• W4292308669 cites W1971837077 @default.
• W4292308669 cites W1986448228 @default.
• W4292308669 cites W1994193851 @default.
• W4292308669 cites W1994993231 @default.
• W4292308669 cites W2005335309 @default.
• W4292308669 cites W2006747130 @default.
• W4292308669 cites W2061345986 @default.
• W4292308669 cites W2070396671 @default.
• W4292308669 cites W2082708772 @default.
• W4292308669 cites W2091425194 @default.
• W4292308669 cites W2126908586 @default.
• W4292308669 cites W2169435545 @default.
• W4292308669 cites W2170369650 @default.
• W4292308669 cites W2570331434 @default.
• W4292308669 cites W2615173525 @default.
• W4292308669 cites W2754562068 @default.
• W4292308669 cites W2790863559 @default.
• W4292308669 cites W2791328450 @default.
• W4292308669 cites W2808205459 @default.
• W4292308669 cites W2891551356 @default.
• W4292308669 cites W2909623835 @default.
• W4292308669 cites W2916357429 @default.
• W4292308669 cites W2933314153 @default.
• W4292308669 cites W2936042979 @default.
• W4292308669 cites W2942775665 @default.
• W4292308669 cites W2986629061 @default.
• W4292308669 cites W2999031113 @default.
• W4292308669 cites W3006120968 @default.
• W4292308669 cites W3023954831 @default.
• W4292308669 cites W3025022288 @default.
• W4292308669 cites W3114332600 @default.
• W4292308669 cites W3122687696 @default.
• W4292308669 cites W3128646645 @default.
• W4292308669 cites W3139581890 @default.
• W4292308669 cites W3165133969 @default.
• W4292308669 cites W3183435229 @default.
• W4292308669 cites W3205381652 @default.
• W4292308669 cites W3205893412 @default.
• W4292308669 cites W4211088407 @default.
• W4292308669 doi "https://doi.org/10.3389/fimmu.2022.963031" @default.
• W4292308669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36059488" @default.
• W4292308669 hasPublicationYear "2022" @default.
• W4292308669 type Work @default.
• W4292308669 citedByCount "4" @default.
• W4292308669 countsByYear W42923086692022 @default.
• W4292308669 countsByYear W42923086692023 @default.
• W4292308669 crossrefType "journal-article" @default.
• W4292308669 hasAuthorship W4292308669A5012143979 @default.
• W4292308669 hasAuthorship W4292308669A5012541451 @default.
• W4292308669 hasAuthorship W4292308669A5014345054 @default.
• W4292308669 hasAuthorship W4292308669A5020392344 @default.
• W4292308669 hasAuthorship W4292308669A5036977660 @default.
• W4292308669 hasAuthorship W4292308669A5046001715 @default.
• W4292308669 hasAuthorship W4292308669A5046597133 @default.
• W4292308669 hasAuthorship W4292308669A5048449740 @default.
• W4292308669 hasAuthorship W4292308669A5052390898 @default.
• W4292308669 hasAuthorship W4292308669A5060427946 @default.
• W4292308669 hasAuthorship W4292308669A5061599798 @default.
• W4292308669 hasAuthorship W4292308669A5065058975 @default.
• W4292308669 hasAuthorship W4292308669A5079375772 @default.
• W4292308669 hasAuthorship W4292308669A5081242848 @default.
• W4292308669 hasAuthorship W4292308669A5091365015 @default.
• W4292308669 hasBestOaLocation W42923086691 @default.
• W4292308669 hasConcept C10205521 @default.
• W4292308669 hasConcept C121608353 @default.
• W4292308669 hasConcept C126322002 @default.
• W4292308669 hasConcept C143998085 @default.
• W4292308669 hasConcept C2777371436 @default.
• W4292308669 hasConcept C2777701055 @default.
• W4292308669 hasConcept C2778019345 @default.
• W4292308669 hasConcept C2778695046 @default.
• W4292308669 hasConcept C2779013556 @default.
• W4292308669 hasConcept C2779742787 @default.
• W4292308669 hasConcept C28328180 @default.
• W4292308669 hasConcept C3875195 @default.
• W4292308669 hasConcept C502942594 @default.
• W4292308669 hasConcept C54355233 @default.
• W4292308669 hasConcept C71924100 @default.
• W4292308669 hasConcept C86803240 @default.

• next